Brazilian Green Propolis Prevents Cognitive Decline into Mild Cognitive Impairment in Elderly People Living at High Altitude

Aiqin Zhu, Hiro Take, Xin Zhong, Junjun Ni, Yinglan Li, Jie Meng, Can Du, Xue Zhao, Hiroshi Nakanishi, Shizheng Wu

Research output: Contribution to journalArticle

Abstract

Background: Systemic inflammation is known as a risk factor of cognitive decline. Objective: To investigate the effects of propolis on cognitive decline and systemic inflammation in elderly people living at high altitude. Methods: Sixty participants (average 72.8 years) living at altitude (2,260 meters) were randomized to receive propolis (0.83g, n=30) or placebo (n=30) for 24 months. Cognitive outcomes were assessed using MMSE and serum cytokine levels were measured for 24 months in a double-blind study. Results: MMSE scores were 26.17 at baseline and 23.87 at 24 months in placebo group. Compared to placebo group, improvements of MMSE scores were significant in propolis-treated subjects (p=0.007) with a response emerging over time (time points×group interaction, p=0.016). In addition, the serum IL-1β and IL-6 levels were significantly different across treatments (p<0.0001) showing upward and downward trends in placebo- and propolis-treated subjects, respectively (p<0.0001). Serum levels of TNF-α were not significantly different across treatment (p=0.0528) but with a response emerging over time (time points×group interaction, p=0.016). In contrast, serum levels of TGFβ1 were significantly different across treatments (p<0.0001) showing downward and upward trends in placebo- and propolis-treated subjects, respectively. Serum levels of IL-10 were significant for the effect of groups (p=0.0411). Furthermore, MMSE scores correlated with the decrease in IL-1β and the increase in TGFβ1 in serum. Conclusion: Elderly people living at high altitude developed to MCI in 24 months with exacerbation of systemic inflammation. Ingestion of propolis (>12 months) protected against cognitive decline after systemic inflammation was reduced.

Original languageEnglish
Pages (from-to)551-560
Number of pages10
JournalJournal of Alzheimer's Disease
Volume63
Issue number2
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Propolis
Placebos
Inflammation
Serum
Interleukin-1
Double-Blind Method
Interleukin-6
Cytokines
Cognitive Dysfunction
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Brazilian Green Propolis Prevents Cognitive Decline into Mild Cognitive Impairment in Elderly People Living at High Altitude. / Zhu, Aiqin; Take, Hiro; Zhong, Xin; Ni, Junjun; Li, Yinglan; Meng, Jie; Du, Can; Zhao, Xue; Nakanishi, Hiroshi; Wu, Shizheng.

In: Journal of Alzheimer's Disease, Vol. 63, No. 2, 01.01.2018, p. 551-560.

Research output: Contribution to journalArticle

Zhu, Aiqin ; Take, Hiro ; Zhong, Xin ; Ni, Junjun ; Li, Yinglan ; Meng, Jie ; Du, Can ; Zhao, Xue ; Nakanishi, Hiroshi ; Wu, Shizheng. / Brazilian Green Propolis Prevents Cognitive Decline into Mild Cognitive Impairment in Elderly People Living at High Altitude. In: Journal of Alzheimer's Disease. 2018 ; Vol. 63, No. 2. pp. 551-560.
@article{d8ba7127be0443009bc4ade2a4901cbf,
title = "Brazilian Green Propolis Prevents Cognitive Decline into Mild Cognitive Impairment in Elderly People Living at High Altitude",
abstract = "Background: Systemic inflammation is known as a risk factor of cognitive decline. Objective: To investigate the effects of propolis on cognitive decline and systemic inflammation in elderly people living at high altitude. Methods: Sixty participants (average 72.8 years) living at altitude (2,260 meters) were randomized to receive propolis (0.83g, n=30) or placebo (n=30) for 24 months. Cognitive outcomes were assessed using MMSE and serum cytokine levels were measured for 24 months in a double-blind study. Results: MMSE scores were 26.17 at baseline and 23.87 at 24 months in placebo group. Compared to placebo group, improvements of MMSE scores were significant in propolis-treated subjects (p=0.007) with a response emerging over time (time points×group interaction, p=0.016). In addition, the serum IL-1β and IL-6 levels were significantly different across treatments (p<0.0001) showing upward and downward trends in placebo- and propolis-treated subjects, respectively (p<0.0001). Serum levels of TNF-α were not significantly different across treatment (p=0.0528) but with a response emerging over time (time points×group interaction, p=0.016). In contrast, serum levels of TGFβ1 were significantly different across treatments (p<0.0001) showing downward and upward trends in placebo- and propolis-treated subjects, respectively. Serum levels of IL-10 were significant for the effect of groups (p=0.0411). Furthermore, MMSE scores correlated with the decrease in IL-1β and the increase in TGFβ1 in serum. Conclusion: Elderly people living at high altitude developed to MCI in 24 months with exacerbation of systemic inflammation. Ingestion of propolis (>12 months) protected against cognitive decline after systemic inflammation was reduced.",
author = "Aiqin Zhu and Hiro Take and Xin Zhong and Junjun Ni and Yinglan Li and Jie Meng and Can Du and Xue Zhao and Hiroshi Nakanishi and Shizheng Wu",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JAD-170630",
language = "English",
volume = "63",
pages = "551--560",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Brazilian Green Propolis Prevents Cognitive Decline into Mild Cognitive Impairment in Elderly People Living at High Altitude

AU - Zhu, Aiqin

AU - Take, Hiro

AU - Zhong, Xin

AU - Ni, Junjun

AU - Li, Yinglan

AU - Meng, Jie

AU - Du, Can

AU - Zhao, Xue

AU - Nakanishi, Hiroshi

AU - Wu, Shizheng

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Systemic inflammation is known as a risk factor of cognitive decline. Objective: To investigate the effects of propolis on cognitive decline and systemic inflammation in elderly people living at high altitude. Methods: Sixty participants (average 72.8 years) living at altitude (2,260 meters) were randomized to receive propolis (0.83g, n=30) or placebo (n=30) for 24 months. Cognitive outcomes were assessed using MMSE and serum cytokine levels were measured for 24 months in a double-blind study. Results: MMSE scores were 26.17 at baseline and 23.87 at 24 months in placebo group. Compared to placebo group, improvements of MMSE scores were significant in propolis-treated subjects (p=0.007) with a response emerging over time (time points×group interaction, p=0.016). In addition, the serum IL-1β and IL-6 levels were significantly different across treatments (p<0.0001) showing upward and downward trends in placebo- and propolis-treated subjects, respectively (p<0.0001). Serum levels of TNF-α were not significantly different across treatment (p=0.0528) but with a response emerging over time (time points×group interaction, p=0.016). In contrast, serum levels of TGFβ1 were significantly different across treatments (p<0.0001) showing downward and upward trends in placebo- and propolis-treated subjects, respectively. Serum levels of IL-10 were significant for the effect of groups (p=0.0411). Furthermore, MMSE scores correlated with the decrease in IL-1β and the increase in TGFβ1 in serum. Conclusion: Elderly people living at high altitude developed to MCI in 24 months with exacerbation of systemic inflammation. Ingestion of propolis (>12 months) protected against cognitive decline after systemic inflammation was reduced.

AB - Background: Systemic inflammation is known as a risk factor of cognitive decline. Objective: To investigate the effects of propolis on cognitive decline and systemic inflammation in elderly people living at high altitude. Methods: Sixty participants (average 72.8 years) living at altitude (2,260 meters) were randomized to receive propolis (0.83g, n=30) or placebo (n=30) for 24 months. Cognitive outcomes were assessed using MMSE and serum cytokine levels were measured for 24 months in a double-blind study. Results: MMSE scores were 26.17 at baseline and 23.87 at 24 months in placebo group. Compared to placebo group, improvements of MMSE scores were significant in propolis-treated subjects (p=0.007) with a response emerging over time (time points×group interaction, p=0.016). In addition, the serum IL-1β and IL-6 levels were significantly different across treatments (p<0.0001) showing upward and downward trends in placebo- and propolis-treated subjects, respectively (p<0.0001). Serum levels of TNF-α were not significantly different across treatment (p=0.0528) but with a response emerging over time (time points×group interaction, p=0.016). In contrast, serum levels of TGFβ1 were significantly different across treatments (p<0.0001) showing downward and upward trends in placebo- and propolis-treated subjects, respectively. Serum levels of IL-10 were significant for the effect of groups (p=0.0411). Furthermore, MMSE scores correlated with the decrease in IL-1β and the increase in TGFβ1 in serum. Conclusion: Elderly people living at high altitude developed to MCI in 24 months with exacerbation of systemic inflammation. Ingestion of propolis (>12 months) protected against cognitive decline after systemic inflammation was reduced.

UR - http://www.scopus.com/inward/record.url?scp=85048374557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048374557&partnerID=8YFLogxK

U2 - 10.3233/JAD-170630

DO - 10.3233/JAD-170630

M3 - Article

C2 - 29630549

AN - SCOPUS:85048374557

VL - 63

SP - 551

EP - 560

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -